Syngene Plans to Triple Bio-Manufacturing Capacity by FY26, Eyes Recovery in H2FY25
Syngene International is optimistic about a recovery in the second half of FY25, as it aims to balance its research-to-manufacturing ratio from 60:40 to 50:50, focusing on stronger growth in manufacturing. The company also plans to triple its bio-manufacturing capacity by FY26. Shares of Syngene closed almost 1% higher at Rs 888, up 25% in […]
Syngene Plans to Triple Bio-Manufacturing Capacity by FY26, Eyes Recovery in H2FY25 Read More »